They first demonstrated that overexpression of AR-V7 precipitated a 2.7-fold and 1.5-fold increase in expression of NFκB in LNCaP and 22Rv1 prostate cancer cells, respectively, further confirmed by a 2-fold increase in a known downstream NFκB target, interleukin (IL)-6 [60]. Here, NFKB1 is linked to prostate cancer.